Suppr超能文献

基于 3D DNA walker 和 CRISPR/Cas12a 的荧光扩增策略用于快速检测 BRAF V600E。

The fluorescence amplification strategy based on 3D DNA walker and CRISPR/Cas12a for the rapid detection of BRAF V600E.

机构信息

Key Laboratory of Medical Diagnostics, Ministry of Education, College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, People's Republic of China.

出版信息

Anal Sci. 2022 Aug;38(8):1057-1066. doi: 10.1007/s44211-022-00131-5. Epub 2022 Jun 3.

Abstract

Circulating tumor DNA (ctDNA) is a fragment of single- or double-stranded DNA originating from tumor or circulating tumor cells and provides accurate information regarding the molecular characteristics of tumors. Therefore, sensitive detection of ctDNA is of great significance to mutation analysis and clinical diagnosis. Among various ctDNAs, the BRAF V600E is related to aggressive behavior, disease recurrence, and disease-specific mortality in papillary thyroid carcinoma. Herein, we selected the BRAF V600E gene sequence as an in vitro biomarker, and established a fluorescence detection strategy combined 3D DNA walker with CRISPR/Cas12a. In the presence of the target ctDNA, 3D DNA walker could identify and bind it, and thus released a large amount of output DNAs through cyclic cleavage with the assistance of specific endonuclease (Nb.BbvCI). The output DNAs were specifically bound to crRNA and activated the non-specific trans-cleavage activity of Cas12a. Finally, the fluorescence signal was significantly enhanced. Notably, this method can detect the BRAF V600E in a range of 1 fM ~ 20 nM with a detection limit of 0.37 fM without DNA polymerase. Due to the powerful amplification capability of 3D DNA walker and high specificity and programmability of CRISPR/Cas12a, the entire process took only a maximum of 70 min. Furthermore, it can be potentially used for the detection of ctDNA in human serum. In summary, this method not only provides a platform for the rapid detection of ctDNA, but also shows good potential for early clinical diagnosis and biomedical research.

摘要

循环肿瘤 DNA(ctDNA)是源自肿瘤或循环肿瘤细胞的单链或双链 DNA 片段,可提供有关肿瘤分子特征的准确信息。因此,对 ctDNA 的敏感检测对于突变分析和临床诊断具有重要意义。在各种 ctDNA 中,BRAF V600E 与甲状腺乳头状癌的侵袭性行为、疾病复发和疾病特异性死亡率有关。在此,我们选择 BRAF V600E 基因序列作为体外生物标志物,建立了一种荧光检测策略,该策略结合了 3D DNA walker 和 CRISPR/Cas12a。在存在靶 ctDNA 的情况下,3D DNA walker 可以识别并与之结合,然后在特定内切酶(Nb.BbvCI)的辅助下通过循环切割释放大量输出 DNA。输出 DNA 特异性地结合到 crRNA 并激活 Cas12a 的非特异性转切割活性。最后,荧光信号显著增强。值得注意的是,该方法可以在 1 fM~20 nM 的范围内检测 BRAF V600E,检测限为 0.37 fM,无需 DNA 聚合酶。由于 3D DNA walker 的强大扩增能力和 CRISPR/Cas12a 的高特异性和可编程性,整个过程仅需最长 70 分钟。此外,它可潜在地用于检测人血清中的 ctDNA。总之,该方法不仅为 ctDNA 的快速检测提供了一个平台,而且对于早期临床诊断和生物医学研究也具有很好的应用潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验